guest ::
| Home > Publications database > Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance. > print |
| Home > Publications database > Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance. > print |
| 001 | 302264 | ||
| 005 | 20250629021243.0 | ||
| 024 | 7 | _ | |a 10.1038/s41467-025-60929-5 |2 doi |
| 024 | 7 | _ | |a pmid:40562773 |2 pmid |
| 024 | 7 | _ | |a altmetric:178352088 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01290 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 500 |
| 100 | 1 | _ | |a Kolb, Antonia |b 0 |
| 245 | _ | _ | |a Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance. |
| 260 | _ | _ | |a [London] |c 2025 |b Springer Nature |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1750941922_1090 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a IκBζ, a rather unknown co-regulator of NF-κB, can either activate or repress a subset of NF-κB target genes. While its role as an inducibly expressed, transcriptional regulator of cytokines and chemokines in immune cells is established, IκBζ's function in solid cancer remains unclear. Here we show that IκBζ protein is constitutively expressed in a subfraction of melanoma cell lines, and around 30% of all melanoma cases, independently of its mRNA levels or known mutations. Deleting IκBζ in melanoma abrogates the activity and chromatin association of STAT3 and NF-κB, thereby reducing the expression of the pro-proliferative cytokines IL-1β and IL-6, thus impairing melanoma cell growth. Additionally, IκBζ suppresses Cxcl9, Cxcl10, and Ccl5 expression via HDAC3 and EZH2, which impairs the recruitment of NK and CD8+ T cells into the tumor, causing resistance to α-PD-1 immunotherapy in mice. Thus, tumor-derived IκBζ may serve as a therapeutic target and prognostic marker for melanoma with high tumor cell proliferation, cytotoxic T- and NK-cell exclusion, and unfavorable immunotherapy responses. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a STAT3 Transcription Factor |2 NLM Chemicals |
| 650 | _ | 7 | |a NF-kappa B |2 NLM Chemicals |
| 650 | _ | 7 | |a Enhancer of Zeste Homolog 2 Protein |0 EC 2.1.1.43 |2 NLM Chemicals |
| 650 | _ | 7 | |a histone deacetylase 3 |0 EC 3.5.1.98 |2 NLM Chemicals |
| 650 | _ | 7 | |a STAT3 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Chemokine CXCL10 |2 NLM Chemicals |
| 650 | _ | 7 | |a Chemokine CCL5 |2 NLM Chemicals |
| 650 | _ | 7 | |a NFKBIZ protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a I-kappa B Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a EZH2 protein, human |0 EC 2.1.1.43 |2 NLM Chemicals |
| 650 | _ | 7 | |a Chemokine CXCL9 |2 NLM Chemicals |
| 650 | _ | 7 | |a Interleukin-6 |2 NLM Chemicals |
| 650 | _ | 7 | |a Histone Deacetylases |0 EC 3.5.1.98 |2 NLM Chemicals |
| 650 | _ | 7 | |a Adaptor Proteins, Signal Transducing |2 NLM Chemicals |
| 650 | _ | 2 | |a Melanoma: genetics |2 MeSH |
| 650 | _ | 2 | |a Melanoma: pathology |2 MeSH |
| 650 | _ | 2 | |a Melanoma: therapy |2 MeSH |
| 650 | _ | 2 | |a Melanoma: immunology |2 MeSH |
| 650 | _ | 2 | |a Melanoma: metabolism |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Cell Line, Tumor |2 MeSH |
| 650 | _ | 2 | |a STAT3 Transcription Factor: metabolism |2 MeSH |
| 650 | _ | 2 | |a Cell Proliferation |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy |2 MeSH |
| 650 | _ | 2 | |a NF-kappa B: metabolism |2 MeSH |
| 650 | _ | 2 | |a Gene Expression Regulation, Neoplastic |2 MeSH |
| 650 | _ | 2 | |a Enhancer of Zeste Homolog 2 Protein: metabolism |2 MeSH |
| 650 | _ | 2 | |a Enhancer of Zeste Homolog 2 Protein: genetics |2 MeSH |
| 650 | _ | 2 | |a CD8-Positive T-Lymphocytes: immunology |2 MeSH |
| 650 | _ | 2 | |a Drug Resistance, Neoplasm: genetics |2 MeSH |
| 650 | _ | 2 | |a Killer Cells, Natural: immunology |2 MeSH |
| 650 | _ | 2 | |a Chemokine CXCL10: genetics |2 MeSH |
| 650 | _ | 2 | |a Chemokine CXCL10: metabolism |2 MeSH |
| 650 | _ | 2 | |a Chemokine CCL5: metabolism |2 MeSH |
| 650 | _ | 2 | |a Chemokine CCL5: genetics |2 MeSH |
| 650 | _ | 2 | |a I-kappa B Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a I-kappa B Proteins: metabolism |2 MeSH |
| 650 | _ | 2 | |a Chemokine CXCL9: metabolism |2 MeSH |
| 650 | _ | 2 | |a Chemokine CXCL9: genetics |2 MeSH |
| 650 | _ | 2 | |a Interleukin-6: metabolism |2 MeSH |
| 650 | _ | 2 | |a Interleukin-6: genetics |2 MeSH |
| 650 | _ | 2 | |a Mice, Inbred C57BL |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Histone Deacetylases |2 MeSH |
| 650 | _ | 2 | |a Adaptor Proteins, Signal Transducing |2 MeSH |
| 700 | 1 | _ | |a Kulis-Mandic, Ana-Marija |b 1 |
| 700 | 1 | _ | |a Klein, Matthias |b 2 |
| 700 | 1 | _ | |a Stastny, Anna |b 3 |
| 700 | 1 | _ | |a Haist, Maximilian |0 0000-0002-6720-7570 |b 4 |
| 700 | 1 | _ | |a Votteler, Vanessa |0 P:(DE-He78)eee8788c339917bc3a391ebb1a00d9a8 |b 5 |u dkfz |
| 700 | 1 | _ | |a Weidenthaler-Barth, Beate |b 6 |
| 700 | 1 | _ | |a Sinnberg, Tobias |0 0000-0003-3922-3327 |b 7 |
| 700 | 1 | _ | |a Sucker, Antje |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Allies, Gabriele |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Albrecht, Lea Jessica |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Tasdogan, Alpaslan |0 0000-0003-2543-852X |b 11 |
| 700 | 1 | _ | |a Tuettenberg, Andrea |b 12 |
| 700 | 1 | _ | |a Gaida, Matthias M |b 13 |
| 700 | 1 | _ | |a Deppermann, Carsten |b 14 |
| 700 | 1 | _ | |a Stege, Henner |b 15 |
| 700 | 1 | _ | |a Schadendorf, Dirk |0 0000-0003-3524-7858 |b 16 |
| 700 | 1 | _ | |a Grabbe, Stephan |b 17 |
| 700 | 1 | _ | |a Schulze Osthoff, Klaus |0 P:(DE-He78)3fc9ad1c0cc7a2172b86374faed6edea |b 18 |u dkfz |
| 700 | 1 | _ | |a Kramer, Daniela |b 19 |
| 773 | _ | _ | |a 10.1038/s41467-025-60929-5 |g Vol. 16, no. 1, p. 5387 |0 PERI:(DE-600)2553671-0 |n 1 |p 5387 |t Nature Communications |v 16 |y 2025 |x 2041-1723 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:302264 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)eee8788c339917bc3a391ebb1a00d9a8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 0000-0003-2543-852X |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 0000-0003-3524-7858 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)3fc9ad1c0cc7a2172b86374faed6edea |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT COMMUN : 2022 |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2024-01-30T07:48:07Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1060 |2 StatID |b Current Contents - Agriculture, Biology and Environmental Sciences |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-02 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NAT COMMUN : 2022 |d 2025-01-02 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2025-01-02 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2025-01-02 |
| 920 | 1 | _ | |0 I:(DE-He78)TU01-20160331 |k TU01 |l DKTK Koordinierungsstelle Tübingen |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)TU01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|